논문 상세보기

대한소화기기능성질환·운동학회> Gut and Liver> Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?

KCI등재

Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?

Dexi Zhou , Jiajie Luan , Cheng Huang , Jun Li
  • : 대한소화기기능성질환·운동학회
  • : Gut and Liver 15권4호
  • : 연속간행물
  • : 2021년 07월
  • : 500-516(17pages)
Gut and Liver

DOI


목차

INTRODUCTION
FUNCTIONAL CHARACTERIZATION OF M2 TAMs IN HCC
EPIGENETIC MODIFICATION OF TAMs AND TUMOR CELLS IN HCC
GUT MICROBIOTA MODULATES TAM FUNCTION AND POLARIZATION IN HCC
TAMs IN HCC THERAPY
CONCLUDING REMARKS
CONFLICTS OF INTEREST
ACKNOWLEDGEMENTS
ORCID
REFERENCES

키워드 보기


초록 보기

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and it has diverse etiologies with multiple mechanisms. The diagnosis of HCC typically occurs at advanced stages when there are limited therapeutic options. Hepatocarcinogenesis is considered a multistep process, and hepatic macrophages play a critical role in the inflammatory process leading to HCC. Emerging evidence has shown that tumor-associated macrophages (TAMs) are crucial components defining the HCC immune microenvironment and represent an appealing option for disrupting the formation and development of HCC. In this review, we summarize the current knowledge of the polarization and function of TAMs in the pathogenesis of HCC, as well as the mechanisms underlying TAM-related anti-HCC therapies. Eventually, novel insights into these important aspects of TAMs and their roles in the HCC microenvironment might lead to promising TAM-focused therapeutic strategies for HCC. (Gut Liver 2021;15:500-516)

UCI(KEPA)

I410-ECN-0102-2022-500-000810747

간행물정보

  • : 의약학분야  > 내과학
  • : KCI등재
  • :
  • : 격월
  • : 1976-2283
  • : 2005-1212
  • : 학술지
  • : 연속간행물
  • : 2007-2022
  • : 1487


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

16권4호(2022년 07월) 수록논문
최근 권호 논문
| | | |

KCI등재

1Role of Tegoprazan in Helicobacter pylori Eradication Therapy

저자 : Jin Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 493-494 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2Is the Risk for Venous Thromboembolism in East Asian Patients with Inflammatory Bowel Disease Comparable to That in Western Patients?

저자 : Sung Wook Hwang

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 495-496 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

3Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions

저자 : Jung Il Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 497-498 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

4Revolution of Novel Direct Peroral Cholangioscopy: Another Step Beyond Limitations

저자 : Tanyaporn Chantarojanasiri

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 499-500 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

5Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease

저자 : Eun Ae Kang , Jae Hee Cheon

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 501-502 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

6Management of Helicobacter pylori Infection: A Comparison between Korea and the United States

저자 : Sung Eun Kim , Joo Ha Hwang

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 503-514 (12 pages)

다운로드

(기관인증 필요)

초록보기

Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries. (Gut Liver 2022;16:503-514)

KCI등재

7Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

저자 : Jia-feng Wu

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 515-524 (10 pages)

다운로드

(기관인증 필요)

초록보기

During the past decade, we have entered an era of biologics for the treatment of Crohn's disease and ulcerative colitis. The therapeutic goal of inflammatory bowel disease (IBD) management has evolved from symptom control and clinical remission to mucosal healing or even deep remission. Histological remission for ulcerative colitis and transmural healing of Crohn's disease are potential future goals. With the adoption of the treat-to-target concept, and given the need for tight control of IBD activity, therapeutic drug monitoring (TDM) is an important element of precision medicine. TDM involves the measurement of serum biologics and anti-drug antibodies levels, to confirm whether the right drug with the right dosage was prescribed to reach the right serum levels. TDM may help clinicians adjust biologics based on objective biomarkers instead of using empirical dosage escalation or making symptom-based therapeutic adjustments. Wellestablished reactive TDM algorithms have been proposed, and emerging evidence supports the clinical application of a proactive TDM strategy to enhance the duration of effective biologics and improve clinical outcomes. Recently, the proactive TDM strategy was shown to avoid the secondary loss of response to biologics, and improve long-term clinical outcomes in IBD patients. This review summarizes data from trials, and practice guidelines, on the clinical application of proactive and reactive TDM strategies for the daily care of biologic-treated IBD patients. (Gut Liver 2022;16:515-524)

KCI등재

8Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy

저자 : Mamoru Takenaka , Masatoshi Kudo

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 525-534 (10 pages)

다운로드

(기관인증 필요)

초록보기

Drainage therapy for malignant biliary obstruction (MBO) includes trans-papillary endoscopic retrograde biliary drainage (ERBD), percutaneous transhepatic biliary drainage (PTBD), and transgastrointestinal endoscopic ultrasound-guided biliary drainage (EUS-BD). With the development of chemotherapy, many MBO cases end up needing endoscopic reintervention (E-RI) for recurrent biliary obstruction. To achieve a successful E-RI, it is necessary to understand the various findings regarding E-RI in MBO cases reported to date. Therefore, in this review, we focus on E-RI for ERBD of distal MBO, ERBD of hilar MBO, and EUS-BD. To plan an appropriate E-RI strategy for biliary stent occlusion for MBO, the following must be considered on a case-by-case basis: the urgency of the drainage, the cause of the occlusion, the original route of drainage (PTBD/ERBD/EUS-BD), the initial stent used (plastic stent or self-expandable metallic stent), and in the case of self-expandable metallic stents, the type used (fully covered or uncovered). Regardless of the original method of stent placement, if the inflammation caused by obstructive cholangitis is severe and/or the patient is in shock, PTBD should be considered as the first choice. Finally, it is important to keep in mind that in many cases, performing E-RI will be difficult. (Gut Liver 2022;16:525-534)

KCI등재

9Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial

저자 : Yoon Jin Choi , Yong Chan Lee , Jung Mogg Kim , Jin Il Kim , Jeong Seop Moon , Yun Jeong Lim , Gwang Ho Baik , Byoung Kwan Son , Hang Lak Lee , Kyoung Oh Kim , Nayoung Kim , Kwang Hyun Ko , Hye-kyung Jung

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 535-546 (12 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.
Methods: A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.
Results: In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.
Conclusions: TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier NCT03317223). (Gut Liver 2022;16:535-546)

KCI등재

10Long-term Outcomes of Additional Endoscopic Treatments for Patients with Positive Lateral Margins after Endoscopic Submucosal Dissection for Early Gastric Cancer

저자 : Tae-se Kim , Byung-hoon Min , Yang Won Min , Hyuk Lee , Poong-lyul Rhee , Jae J. Kim , Jun Haeng Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 16권 4호 발행 연도 : 2022 페이지 : pp. 547-554 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: It is uncertain whether additional endoscopic treatment may be chosen over surgery in patients with positive lateral margins (pLMs) as the only non-curative factor after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to compare the long-term outcomes of additional endoscopic treatments in such patients with those of surgery and elucidate the clinicopathological factors that could influence the treatment selection.
Methods: A total of 99 patients with 101 EGC lesions undergoing additional treatment after noncurative ESD with pLMs as the only non-curative factor were analyzed. Among them, 25 (27 lesions) underwent ESD, 29 (29 lesions) underwent argon plasma coagulation (APC), and 45 (45 lesions) underwent surgery. Clinicopathological characteristics and long-term outcomes were compared.
Results: Residual tumor was found in 73.6% of cases. The presence of multiple pLMs was associated with higher risk of residual tumor (p=0.046). During a median follow-up of 58.9 months, recurrent or residual lesions after additional ESD and APC were found in 4% (1/25) and 6.8% (2/29) of patients, respectively. However, all were completely cured with surgery or repeated ESD. There were no extragastric recurrences after additional endoscopic treatment. Lymph node metastasis was identified after additional surgery in one (2.2%) patient with an EGC showing histological heterogeneity.
Conclusions: Given the favorable long-term outcomes, additional ESD or APC may be an acceptable choice for patients with pLMs as the only non-curative factor after ESD for EGC. However, clincopathological characteristics such as multiple pLMs and histological heterogeneity should be considered in the treatment selection. (Gut Liver 2022;16:547-554)

12
권호별 보기
같은 권호 다른 논문
| | | | 다운로드

KCI등재

1Benefits of a Molecular-Based Method for the Detection of Clarithromycin-Resistant Helicobacter pylori

저자 : Batsaikhan Saruuljavkhlan , Yoshio Yamaoka

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 487-489 (3 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

2Direct Hyperbilirubinemia as a Predictor of Mortality in Patients with Liver Cirrhosis

저자 : Chang Hun Lee , In Hee Kim

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 490-491 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재

3Current Status of Mucosal Imaging with Narrow-Band Imaging in the Esophagus

저자 : Keng Hoong Chiam , Seon Ho Shin , Kun Cheong Choi , Florencia Leiria , Mariana Militz , Rajvinder Singh

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 492-499 (8 pages)

다운로드

(기관인증 필요)

초록보기

Recent advances in endoscopic imaging of the esophagus have revolutionized the diagnostic capability for detecting premalignant changes and early esophageal malignancy. In this article, we review the practical application of narrow-band imaging focusing on diseases of the esophagus, including Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. (Gut Liver 2021;15:492-499)

KCI등재

4Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?

저자 : Dexi Zhou , Jiajie Luan , Cheng Huang , Jun Li

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 500-516 (17 pages)

다운로드

(기관인증 필요)

초록보기

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and it has diverse etiologies with multiple mechanisms. The diagnosis of HCC typically occurs at advanced stages when there are limited therapeutic options. Hepatocarcinogenesis is considered a multistep process, and hepatic macrophages play a critical role in the inflammatory process leading to HCC. Emerging evidence has shown that tumor-associated macrophages (TAMs) are crucial components defining the HCC immune microenvironment and represent an appealing option for disrupting the formation and development of HCC. In this review, we summarize the current knowledge of the polarization and function of TAMs in the pathogenesis of HCC, as well as the mechanisms underlying TAM-related anti-HCC therapies. Eventually, novel insights into these important aspects of TAMs and their roles in the HCC microenvironment might lead to promising TAM-focused therapeutic strategies for HCC. (Gut Liver 2021;15:500-516)

KCI등재

5Management of Gallstones and Acute Cholecystitis in Patients with Liver Cirrhosis: What Should We Consider When Performing Surgery?

저자 : Shang Yu Wang , Chun Nan Yeh , Yi Yin Jan , Miin Fu Chen

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 517-527 (11 pages)

다운로드

(기관인증 필요)

초록보기

Acute cholecystitis and several gallbladder stone-related conditions, such as impacted common bile duct stones, cholangitis, and biliary pancreatitis, are common medical conditions in daily practice. An early cholecystectomy or drainage procedure with delayed cholecystectomy is the current standard of treatment based on published clinical guidelines. Cirrhosis is not only a condition of chronically impaired hepatic function but also has systemic effects in patients. In cirrhotic individuals, several predisposing factors, including changes in the bile acid composition, increased nucleation of bile, and decreased motility of the gallbladder, contribute to the formation of biliary stones and the possibility of symptomatic cholelithiasis, which is an indication for surgical treatment. In addition to these predisposing factors for cholelithiasis, systemic effects and local anatomic consequences related to cirrhosis lead to anesthesiologic risks and perioperative complications in cirrhotic patients. Therefore, the treatment of the aforementioned biliary conditions in cirrhotic patients has become a challenging issue. In this review, we focus on cholecystectomy for cirrhotic patients and summarize the surgical indications, risk stratification, surgical procedures, and surgical outcomes specific to cirrhotic patients with symptomatic cholelithiasis. (Gut Liver 2021;15:517-527)

KCI등재

6Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori

저자 : Sang Yoon Kim , Jae Myung Park , Chul-hyun Lim , Hye Ah Lee , Ga-yeong Shin , Younghee Choe , Yu Kyung Cho , Myung-gyu Choi

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 528-536 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Point mutations in the 23S ribosomal RNA gene have been associated with Helicobacter pylori clarithromycin resistance. This study aimed to detect the prevalence of these point mutations and to investigate the role of different point mutations in the success of eradication therapy.
Methods: We retrospectively investigated a total of 464 consecutive patients who underwent an endoscopic examination and dual-priming oligonucleotide-based multiplex polymerase chain reaction for H. pylori between June 2014 and October 2019. For 289 patients with negative point mutations, standard triple therapy was used in 287 patients, and the bismuth-quadruple regimen was used in two patients. For 175 patients with positive point mutations (A2142G, A2143G, and both mutations), standard triple and bismuth-quadruple therapies were used in 37 patients and 138 patients, respectively.
Results: The eradication rates of standard triple and bismuth-quadruple therapies showed no significant difference in mutation-negative patients or those with the A2142G point mutation. However, the eradication rate with bismuth-quadruple therapy was significantly higher than that with standard triple therapy in the group with the A2143G mutation or with the double mutation. The eradication rates for standard triple and bismuth-quadruple therapies, respectively, were 25.8% and 92.1% in the per-protocol group (p<0.001) and 24.2% and 85.2% in the intention-totreat analysis (p<0.001).
Conclusions: The A2143G point mutation is the most prevalent cause of clarithromycin resistance. Bismuth-quadruple therapy is superior to standard triple therapy in patients with the A2143G or double point mutation. (Gut Liver 2021;15:528-536)

KCI등재

7Clinical Significance of TWIST-Positive Circulating Tumor Cells in Patients with Esophageal Squamous Cell Carcinoma

저자 : Hyun Jung Lee , Gwang Ha Kim , Su Jin Park , Chae Hwa Kwon , Moon Won Lee , Bong Eun Lee , Dong Hoon Baek , Hoseok I

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 533-541 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Unlike other gastrointestinal tract cancers, there are relatively few reports on the clinical significance of circulating tumor cells (CTCs) and TWIST, a marker of epithelial-mesenchymal transition, in patients with esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the clinical significance of TWIST expression in CTCs in patients with ESCC.
Methods: Peripheral blood samples for CTC analyses were prospectively obtained from 52 patients with ESCC prior to treatment between September 2017 and September 2019. CTCs were detected using a centrifugal microfluidic system based on a fluid-assisted separation technique, and CTCs positive for TWIST on immunostaining were defined as TWIST (+) CTCs.
Results: Of the 52 patients with ESCC, CTCs and TWIST (+) CTCs were detected in 44 patients (84.6%) and 39 patients (75.0%), respectively. The CTC and TWIST (+) CTC counts were significantly higher in patients aged >65 years and those who had a large tumor (>3 cm) than in those aged ≤65 years and those who had a small tumor (≤3 cm), respectively. There were no differences in CTC and TWIST (+) CTC counts according to tumor location, histologic grade, or TNM stage. TWIST (+) CTCs were significantly associated with histologic grade; a proportion of TWIST (+) CTCs ≥0.5 was significantly associated with advanced histologic grade. Other clinicopathologic characteristics such as sex, age, tumor location, tumor size, and TNM stages were not significantly associated with TWIST (+) CTCs.
Conclusions: Our study showed that TWIST (+) CTCs were frequently detected in patients with ESCC, and a high proportion of TWIST (+) CTCs was associated with poor differentiation. (Gut Liver 2021;15:553-561)

KCI등재

8A Nationwide Cohort Study Shows a Sex-Dependent Change in the Trend of Peptic Ulcer Bleeding Incidence in Korea between 2006 and 2015

저자 : Yong Sung Kim , Joonki Lee , Aesun Shin , Jung Min Lee , Jong Heon Park , Hwoon-yong Jung

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 537-545 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: The incidence of peptic ulcer disease has decreased in past decades; however, the trends in peptic ulcer bleeding (PUB) are inconsistent among regions. This study aimed to investigate the trends in PUB incidence and the effect of risk factors on PUB in Korea.
Methods: The records of patients hospitalized with PUB from 2006 to 2015 were retrieved from the Korean National Health Insurance Service Database. Standardized incidences of PUB were calculated, and the clinical characteristics such as age, sex, Helicobacter pylori infection, drug exposure, comorbidities, and mortality were obtained.
Results: In total, 151,507 hospitalizations with PUB were identified. The overall annual hospitalization rate was 34.98 per 100,000 person-years. The incidence of PUB showed no significant change from 2006 to 2008 and decreased from 2008 to 2015, with an annual change of -2.7% (p<0.05); however, this change was only significant in men. The incidence of PUB was higher in men than in women between 40 and 70 years old and higher in women than in men older than 80 years. From 2006 to 2015, the H. pylori infection rate increased significantly in patients with PUB; however, there was no significant change in exposure to nonsteroidal anti-inflammatory drugs or other drugs that increase the risk of PUB.
Conclusions: Over the past decade, the incidence of PUB has decreased in a sex-specific manner. There has been a decreasing trend in the H. pylori infection rate and no change in exposure to drugs that increase the risk of PUB in Korea. (Gut Liver 2021;15:537-545)

KCI등재

9The Usefulness of the Measurement of Esophagogastric Junction Distensibility by EndoFLIP in the Diagnosis of Gastroesophageal Reflux Disease

저자 : Jung Min Lee , In Kyung Yoo , Eunju Kim , Sung Pyo Hong , Joo Young Cho

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 546-552 (7 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Increased esophagogastric junction (EGJ) relaxation is the most important mechanism involved in gastroesophageal reflux disease (GERD). An endoscopic functional luminal imaging probe (EndoFLIP) is a device used to quantify EGJ distensibility in routine endoscopy. The aim of the current study was to assess the usefulness of EndoFLIP for the diagnosis of GERD compared to normal controls.
Methods: We analyzed EndoFLIP data from 204 patients with erosive reflux disease (ERD), 310 patients with nonerosive reflux disease (NERD), and 277 normal subjects. EndoFLIP uses impedance planimetry to measure 16 cross-sectional areas (CSAs) in conjunction with the corresponding intrabag pressure within a 4.6 cm cylindrical segment of a fluid-filled bag. The EGJ distensibility was assessed using 40 mL volume-controlled distensions.
Results: The mean distensibility index values were 13.98 ㎟/mm Hg in ERD patients, 11.42 ㎟/mm Hg in NERD patients, and 9.1 ㎟/mm Hg in normal subjects. There were significant differences in EGJ distensibility among the three groups (p<0.001). In addition, the CSAs were significantly higher in the ERD (291.03±160.77 ㎟) and NERD groups (285.87±155.47 ㎟) than in the control group (249.78±144.76 ㎟, p=0.004). We determined the distensibility index cutoff value of EGJ as 10.95 for the diagnosis of GERD by receiver operating characteristic curve analysis.
Conclusions: The EGJ distensibilities of GERD patients were higher than those of normal subjects, regardless of the presence of reflux esophagitis. Thus, the measurement of EGJ distensibility using the EndoFLIP system could be useful in the diagnosis of GERD. (Gut Liver 2021;15:546-552)

KCI등재

10Pain Intensity at Injection Site during Esophagogastroduodenoscopy Using Long- and Medium- Chain versus Long-Chain Triglyceride Propofol: A Randomized Controlled Double-Blind Study

저자 : Joon Seop Lee , Eun Soo Kim , Kwang Bum Cho , Kyung Sik Park , Yoo Jin Lee , Ju Yup Lee

발행기관 : 대한소화기기능성질환·운동학회 간행물 : Gut and Liver 15권 4호 발행 연도 : 2021 페이지 : pp. 562-568 (7 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: The intensities of injection pain resulting from the use of long- and mediumchain triglyceride (LCT/MCT) propofol and conventional LCT propofol during esophagogastroduodenoscopy (EGD) have yet to be compared. We aimed to determine the pain intensity caused by different formulations of propofol and to evaluate the formulation that would be preferred by patients as a sedative agent during their next procedure.
Methods: This study was a single-center, randomized, controlled, and double-blind trial. Pain intensity was estimated 30 seconds after propofol injection by an examiner who was blinded to the group assignment using a numeric (0-10) pain rating scale (NPRS). After 1 week, the patients were asked whether they could recall the pain and were willing to receive the same agent for their next EGD.
Results: One hundred twenty-nine patients were randomly assigned to LCT/MCT or LCT group. Although there was no significant difference in pain incidence between the LCT/MCT and LCT groups (52.9% vs 65.6%, p=0.156), the pain intensity was significantly lower in the LCT/MCT group (NPRS median [interquartile range]; 1 (0-2) vs 2 (0-5), p=0.005). After 1 week, fewer patients in the LCT/MCT group recalled the pain (19.1% vs 63.9%, p<0.001) and more patients in the LCT/MCT group were more willing to use the same agent for their next procedure (86.8% vs 72.1%, p=0.048) than in the LCT group.
Conclusions: LCT/MCT propofol significantly reduced injection pain intensity compared to LCT propofol during EGD and preferred by patients as a sedative agent during their next EGD. (Gut Liver 2021;15:562-568)

12
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기